Feasibility of Administering Clonidine as a Pharmacological Challenge in Imaging Studies (a2a Agonist)

NCT04030572 EARLY_PHASE1 TERMINATED

This will be a Phase 1, open label study of the pharmacokinetics (PK) and pharmacodynamics (PD) of clonidine, an alpha-2 adrenergic (a2a) agonist, in healthy volunteers. The primary aim is to show that the drug regimen is safe and reasonably well tolerated. The secondary aim is to demonstrate that safety can be monitored with home health devices.

Details

Lead sponsor	Weill Medical College of Cornell University
Phase	EARLY_PHASE1
Status	TERMINATED
Enrolment	3
Start date	Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Mar 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Neuro-Degenerative Disease
• Cancer

Interventions

• Clonidine Pill

Countries

United States